Company intelligence / Profile preview

Forbius

Austin, Texas, United Statesforbius.com ↗

Ownership: Private
Development stage: Phase 2

Overview

AVID200 is a highly potent, isoform-selective inhibitor of TGF-beta1 and TGF-beta3 designed to neutralize these drivers of fibrosis and tumor immune resistance while sparing TGF-beta2 to avoid hematopoietic/cardiac side effects. This selective inhibition is proposed to enhance anti-tumor efficacy synergistically with immunotherapy as well as provide anti-fibrotic benefits[2][3].

Therapeutic areas: OncologyRare Diseases
Modalities: Protein engineering-based biotherapeuticsSelective TGF-beta isoform inhibitors
Industry: Biotech

Drug pipeline

2 assets

AVID200

Phase 1

Indications: Solid tumors, Fibrosis

1 more asset in the full pipeline.

Request access →

Partnerships

Acquired by Bristol Myers Squibb who now develops the lead programs further[3]

Beyond the preview

Go deeper on Forbius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forbius.

Explore the full profile